Airbus restructures defence division amid challenging business environment

Guillaume Faury Chief Executive Officer Airbus Airbus SE
Guillaume Faury Chief Executive Officer Airbus - Airbus SE
0Comments

Munich, Germany – Airbus Defence and Space is set to implement a new organizational structure starting July 1, 2025. This follows the completion of necessary information and consultation processes at both European and national levels, resulting in agreements with social partners.

The restructuring was first announced in October 2024 as a response to ongoing challenges within the business environment, particularly affecting the Space Systems segment. The company faced significant financial charges during 2023 and 2024.

The plan includes reducing up to 2,043 positions, mainly targeting management overhead functions. This move aims to enhance accountability across its three business lines: Air Power, Space Systems, and Connected Intelligence.

Mike Schoellhorn, CEO of Airbus Defence and Space, stated: “I thank our social partners and our Airbus Defence and Space colleagues for their constructive engagement and contributions throughout this process. Navigating organisational change is never straightforward for any party, particularly when it involves adapting our workforce. The current geopolitical landscape requires a stronger, faster and more resilient European defence and security industry. Our new structure delivers on this requirement through an efficient and effective end-to-end responsibility for our three businesses and a significantly optimised cost structure while preserving the ability and capacity to benefit from growing defence spending.”

There will be no compulsory redundancies as part of this restructuring effort. The company has committed to minimizing impacts on employees by using all available social measures.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.